CETSA quantitatively verifies in vivo target engagement of novel RIPK1 inhibitors in various biospecimens.

about

Thymoquinone Suppresses IRF-3-Mediated Expression of Type I Interferons via Suppression of TBK1.

P2860

Q54110520-CEC1212E-AA5B-41BE-9A1B-93CED5BD5DA1

P2860

CETSA quantitatively verifies in vivo target engagement of novel RIPK1 inhibitors in various biospecimens.

Item

http://www.wikidata.org/entity/Q42376104

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

CETSA quantitatively verifies ...... itors in various biospecimens.

@en

CETSA quantitatively verifies ...... itors in various biospecimens.

@nl

type

Item

label

CETSA quantitatively verifies ...... itors in various biospecimens.

@en

CETSA quantitatively verifies ...... itors in various biospecimens.

@nl

prefLabel

CETSA quantitatively verifies ...... itors in various biospecimens.

@en

CETSA quantitatively verifies ...... itors in various biospecimens.

@nl

P1476

CETSA quantitatively verifies ...... itors in various biospecimens.

@en

P2093

Manabu Mochizuki

http://www.w3.org/2001/XMLSchema#string

Masako Kuno

http://www.w3.org/2001/XMLSchema#string

Masanori Nakakariya

http://www.w3.org/2001/XMLSchema#string

Masato Yoshikawa

http://www.w3.org/2001/XMLSchema#string

Misa Iwatani-Yoshihara

http://www.w3.org/2001/XMLSchema#string

Sachio Shibata

http://www.w3.org/2001/XMLSchema#string

Satoko Unno

http://www.w3.org/2001/XMLSchema#string

Takatoshi Yogo

http://www.w3.org/2001/XMLSchema#string

Takuro Okai

http://www.w3.org/2001/XMLSchema#string

Tomohiro Kawamoto

http://www.w3.org/2001/XMLSchema#string

P2860

Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha

Target engagement in lead generation

CETSA screening identifies known and novel thymidylate synthase inhibitors and slow intracellular activation of 5-fluorouracil.

Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis

The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism

DNA-Encoded Library Screening Identifies Benzo[b][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase Inhibitors

Identification of RIP1 kinase as a specific cellular target of necrostatins

Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury

RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS.

Positron emission tomography molecular imaging for drug development.

P2888

s41598-017-12513-1

P304

13000

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-017-12513-1

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092102083

http://www.w3.org/2001/XMLSchema#string

P698

29026104

http://www.w3.org/2001/XMLSchema#string

P932

5638916

http://www.w3.org/2001/XMLSchema#string

CETSA quantitatively verifies in vivo target engagement of novel RIPK1 inhibitors in various biospecimens.

about

P2860

P2860

CETSA quantitatively verifies in vivo target engagement of novel RIPK1 inhibitors in various biospecimens.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P6179

P698

P932